FREDERICK, Md., Feb. 10 (UPI) -- Molecular diagnostics company Akonni Biosystems of Maryland has signed a license agreement for use of U.S. Army bio-security research.
The agreement gives Akonni full access, under patents owned or licensed by the U.S. Army Medical Research Institute for Infectious Diseases and its affiliates, to the nucleic acid sequences, primers and probes for many of the most important biological threat agents.
Having access to this content will allow Akonni Biosystems to more rapidly commercialize a family of highly multiplexed tests for research and in vitro diagnostics uses in global bio-security applications.
"We are excited to partner with USAMRIID on developing a series of low-cost, multiplex testing products to protect our warfighters, first responders and citizens from many of the most dangerous bio-threat agents known to man," said Akonni Chief Executive Officer Charles Daitch.
"Our engineering, manufacturing and quality systems expertise, coupled with USAMRIID's expertise in biological assay development, creates a very powerful combination for delivering a new generation of rapid, low-cost bio-security products to the marketplace."
Akonni said it plans to develop a family of products that expands its market presence beyond tests that detect infectious diseases. The new markets include global bio-security, where the rapid and low-cost detection of Category A bio-threat bacterial and viral agents is critical.